DOAC in Unusual Site Venous Thrombosis

International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03778502

Acronym

DUST

Enrollment

358

Registered

2018-12-19

Start date

2019-10-01

Completion date

2024-12-31

Last updated

2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis

Brief summary

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.

Interventions

DRUGDirect Oral Anticoagulants

Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs and pulmonary arteries * Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)

Exclusion criteria

• Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site VTE

Design outcomes

Primary

Measure	Time frame	Description
Rationale for the use of the direct oral anticoagulants	Baseline	Possible reasons for choosing one of the direct oral anticoagulant (multiple choice question)

Secondary

Measure	Time frame
Rate of major bleeding events	12 months
Rate of vascular events	12 months

Countries

Canada, France, Israel, Italy, Malta, Netherlands, Slovenia, Spain, Thailand, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026